RVL Pharmaceuticals plc reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 10.02 million compared to USD 2.2 million a year ago. Net loss was USD 14.45 million compared to USD 17.86 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.42 a year ago. Basic loss per share was USD 0.16 compared to USD 0.28 a year ago.
For the nine months, revenue was USD 39.91 million compared to USD 14.64 million a year ago. Net loss was USD 33.37 million compared to USD 45.2 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 1.01 a year ago. Basic loss per share was USD 0.39 compared to USD 0.72 a year ago.